Abstract submission is now closed.
Please see below for the list of oral presentation selections.
- #578 Cost per Responder in Brazil (EASI-75, EASI90 and ∆NRS ≥4) of biologics and JAK inhibitors Based on a Network-Meta-Analysis of Therapies for Atopic Dermatitis
Guilherme Muzy - #594 United States Prevalence of Atopic Dermatitis in Adults by Race and Ethnicity
Andrew Alexis, Dave Nelson, Candrice Heath, Russel Burge, Beth Mitchell, Andrea Cohee, Evangeline Pierce, Amber Reck Atwater, Raj Chovatiya - #603 Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2–11 years: 52 week results from a maximum-use trial
Robert Bissonnette, MD, Mark S. Lee, MD, Seth B. Forman, MD, Linda Stein Gold, MD, PhD, Howard Kallender, PhD, Brett Angel, MD, Yutzu Kuo, PhD, Amy S. Paller, MD - #625 Efficacy and safety of 1.5% ruxolitinib cream in patients with facial and/or neck atopic dermatitis: a randomized, double-blind, decentralized phase 2 study
Zelma C. Chiesa Fuxench, MD, MSCE, Zhihong Lai, PhD, YuTzu Kuo, PhD, Haq Nawaz, MD, MPH, MBA, MS, Jonathan Cotliar, MD - #638 Long-term safety and efficacy of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis: a 52-week, phase 3, open-label extension trial
Eric L. Simpson, Lawrence F. Eichenfield, Kim A. Papp, Seth Forman, Adelaide A. Hebert, Mercedes E.Gonzalez, Melinda Gooderham, H. Chih-ho Hong, Vimal H. Prajapati, Emma Guttman, Jonathan Silverberg, Melissa Seal, David Krupa, Patrick Burnett, Scott Synder, David H. Chu, Robert C. Higham, David R. Berk - #647 Upadacitinib dose alterations in adolescent and adult patients with atopic dermatitis: a real-world multicenter retrospective review
Siddhartha Sood (HBSc), Brian D. Rankin (MD, PhD), Ye-Jean Park, Alexander Rimke (MSc), Abrahim Abduelmula (MD), Jorge R. Georgakopoulos (MD), Khalad Maliyar (MD), Fernejoy Leung, Lauren A. Stark Alim R. Devani (MD, FRCPC), Jensen Yeung (MD, FRCPC), Vimal H. Prajapati (MD, FRCPC) - #659 Positive patient-reported outcomes following treatment of stable vitiligo with autologous skin cell suspension transplantation prepared by a point-of-care cell harvesting device
Nanette B. Silverberg, MD and the RSVP Study Vitiligo Working Group - #665 Lack of publications assessing patient impact of vitiligo and alopecia areata
Sarah Brown, Emily Chastain, Kaylen Suryajaya, Sarah Feaver, and Stephanie Harbers - #668 Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)
Jonathan I Silverberg, Andreas Wollenberg, Franz J Legat, Vivian T Laquer, Liliana Ulianov, Soo Yeon Cheong, Anna Ryzhkova, Christophe Piketty - #674 Patient-reported outcomes for GSK1070806, an anti-IL-18 monoclonal antibody: a phase 1b, randomised, double-blind, parallel-group placebo-controlled study of patients with atopic dermatitis
Parima Ghafoori, PharmD, Lea Fortunato, PhD, Dharm S. Patel, PhD, Joanne Ellis, PhD, Gabriel Wong, MD, John B. Kelly, MD, PhD, Helen Birch, PhD, Wen-Hung Chen, PhD, Iain Uings, BSc - #677 Establishing a patient-centered definition of atopic dermatitis flare: insights from a modified eDelphi study
Wendy Smith Begolka, Isabelle J C Thibau, Bryan Mantell, Katie N Dainty, Mathew Wyke, Aaron M Drucker - #683 Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study
Christopher G. Bunick, Ayman Grada, James Del Rosso, April W. Armstrong, Emma Yue, Whitney Krueger - #687 Treatment of conjunctivitis in dupilumab-treated patients with atopic dermatitis: an observational study
Penny Asbell, Esen K. Akpek, Winston Chamberlain, Zhen Chen, Anna Coleman, Ana B. Rossi, Brad Shumel - #688 The heterogeneous characteristics of itch vary by atopic dermatitis severity and differentially impact quality of life in children and adults: a prospective cohort study
Brandon Ansbro, BA; Jonathan I. Silverberg, MD, PhD, MPH - #693 Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS)
Jonathan Silverberg, Lawrence Eichenfield, Andrew Blauvelt, Alan D Irvine, Richard Langley, Emma Guttman, Richard Warren, Lars French, Claus Bang Pedersen, Anna Carlsson, Morten Lind Jensen, Morten O. A. Sommer, Kim Kjøller, Eric Simpson - #695 Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis
Lisa A. Beck, Eric L. Simpson, Diamant Thaçi, Marjolein de Bruin-Weller, Mette Deleuran, Yoko Kataoka, Adam J. Friedman, Faisal A. Khokhar, Anna Coleman, Guy Gherardi, Zhen Chen, Elena Avetisova, Annie Zhang, Tien V. Nguyen - #696 Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
Vimal H. Prajapati, Christopher G Bunick, Kilian Eyerich, Linda Stein Gold, Fabrizio Galimberti, Brian Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Cristina Sancho, Ayman Grada, Alan D Irvine - #698 Impact of amlitelimab (an anti-OX40 Ligand antibody) on clinical outcome assessments for atopic dermatitis: results from the 52-week STREAM-AD phase 2b study in adults with moderate-to-severe atopic dermatitis
Andrew Blauvelt; Raj Chovatiya; Joseph F. Merola; Stephan Weidinger; Ken Igawa; Efstathios Zikos; Christine Weber; Jennifer Wang; Cori Gray - #699 Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study
Arash Mostaghimi, April W Armstrong, Ayman Grada, Ahmed M Soliman, Chao Li, Claire C Bristow, Dawid Lipiszko, Jonathan I Silverberg, Naiem T Issa, Christopher G Bunick - #705 Patient preferences for atopic dermatitis treatment profiles: results from a discrete choice experiment
Matthew Quaife, Sarah Mulnick, Harrison Clarke, Kerry Noonan, Gaelle Le-Bagousse-Bego, Debra Sierka, El-Bdaoui Haddad, Raj Chovatiya - #706 Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study
Jonathan I Silverberg, Brian M Calimlim, Zelma C Chiesa Fuxench, Katherine Altman, Arielle G Bensimon, Jiaxuan Liu, Christopher G Bunick - #708 Raising the bar of efficacy in atopic dermatitis: lebrikizumab maintains depth of response over 2 years
Eric Simpson, Tilo Biedermann, Leon Kircik, Raj Chovatiya, Ignasi Figueras-Nart, Marta Casillas, Gaia Gallo, Yuxin Ding, Chaoran Hu, Evangeline Pierce, Helena Agell, Christian Vestergaard - #712 Positive 52-week maintenance data observed with rademikibart in patients with moderate-to-severe atopic dermatitis (SEASIDE CHINA)
Jianzhong Zhang, Jonathan I. Silverberg, Jiawang Guo, Jili Yun, Wuban Pan, Zheng Wei, Raúl Collazo - #717 Clinical Efficacy, Safety, and Pharmacokinetic Profile of Bosakitug (BSI-045B), an Anti-Thymic Stromal Lymphopoietin (TSLP) mAb in a Phase 2 Study of Moderate and Severe Atopic Dermatitis Subjects
Jennifer L. Parish, James E. Appel, Jonathan I. Silverberg, Chu Zhang, Shu-Wen Teng, Jing Zhang, Qinghua Yu, Xiaodong F. Liu, Mingjiu Chen and Hugh M. Davis - #719 Modulating Nav1.8-expressing neurons offers promising direction to address symptoms of atopic dermatitis
Madeline C. Scoles, Jacqueline C. Wang, Winnie Sung, Mason Olivarez, Ellen Liu, Emmy Lev, Rishi B. Shah, Seongmin Kim, Nihal Kaplan, Amy S. Paller - #720 Comparative analysis of the ABCB5 gene expression in perilesional vitiligo and normal skin biopsies
Verónica Mondragón-Luna, Martha Alejandra Morales Sanchez, Gabriela Rebeca Luna Palencia, Ricardo Jaime-Cruz, Ismael Vásquez-Moctezuma - #725 The TCS/TCI-free rate remains high and stable while on lebrikizumab for treatment of moderate-to-severe atopic dermatitis over 1 year
James Del Rosso, Audrey Nosbaum, Alexandra Golant, Takeshi Nakahara, Jenny E. Murase, Andrew Pink, Sonia Montmayeur, Meihua Qiao, Sherry Chen, Ignasi Pau-Charles, Thomas Bieber - #732 EASI 90 response sustained up to 38 weeks after lebrikizumab withdrawal despite negligible serum concentrations
Jonathan I. Silverberg, Thomas Bieber, Kilian Eyerich, April W. Armstrong, Brian J Nickoloff, Chitra R Natalie, Gaia Gallo, Angela Okragly, Chenjia Xu, Brian Moser, Maria Jose Rueda, Hany Elmaraghy, Ozge Uluckan, Johann E. Gudjonsson - #733 Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data
Jonathan I Silverberg, Linda Stein-Gold, Diamant Thaçi, Andrew E Pink, Kim A Papp, Franz J Legat, Vivian T Laquer, Soo Yeon Cheong, Liliana Ulianov, Anna Ryzhkova, Christophe Piketty - #734 Efficacy and safety of upadacitinib vs dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up)
Jonathan I. Silverberg, Christopher Bunick, H. Chih-ho Hong, Pedro Mendes-Bastos, Linda Stein Gold, Antonio Costanzo, Nadia Ibrahim, Cristina Sancho, Xiaoqiang Wu, Yu Han, Gweneth Levy, Kathy Altman, Kilian Eyerich
Abstract Submission FAQs and Guidelines - June 2024 Conference
Important Dates
Abstract Submission
Opens Wednesday, February 7, 2024
Abstract Submission Deadline
Wednesday, May 1, 2024 (11:59 PM ET)
Abstract Acceptance Notifications
Rolling - notifications will be emailed to the submitter's email address within approximately 1 week of abstract submission
Late Breaker Submission Deadline
Tuesday, May 7, 2024 (5:00 PM ET)
Oral Acceptance Notifications (See below for additional requirements if accepted for an Oral Presentation)*
Notification: Week of May 13, 2024
YOU MUST ATTEND THE CONFERENCE IN PERSON IN CHICAGO IN ORDER TO PRESENT.
(Please see below for additional requirements if accepted for an Oral Presentation.)
Final Poster and Abstract for Electronic Posting
Friday, May 31, 2024 (11:59 PM ET)
Important Information Regarding Poster and Oral Presentations
If the primary author is unable to present, a co-author may present. For oral presentations that are being presented during the late-breaking session at the podium, the presenter may not be a member of industry.
Important Information Regarding Oral Presentations*
Please be aware of the following dates and requirements in the event you are selected:
A list of abstracts that have been accepted as oral presentations will be posted on the Conference Agenda by Friday, May 17, 2024. *Wednesday, May 29, 2024 (11:59 PM ET) - Presentations must be submitted for CME approval. Format will be PPT. There will be no extensions. More details to follow upon acceptance.
Frequently Asked Questions (FAQs)
Is there an abstract submission fee?
Yes - US $125.00
Are there rules about previous presentations and adaptations of data at conferences and in publications?
Encore and adapted presentations are permitted. All abstracts will undergo review by the Abstract Review Committee who will assess for scientific merit and novelty. The submitting author must provide the name of the conference/publication, presentation/publication date and presentation venue.
Is a trial-in-progress abstract allowed?
Yes
Is there an author limit for abstracts?
No
Is there a word limit or character count to which we should adhere?
600 words; 1 chart or graph is allowed (word count does not include title, authors, author affiliations, references or disclosures; there is no limit to the number of references allowed)
Who owns the copyright on the accepted abstract/presentation?
The authors own all copyright to their accepted abstract(s)/presentation(s).
May a non-author present on behalf of the authors?
- Yes, for non-accredited poster presentations (i.e.: those that are being presented in the poster hall)
- No, for accredited poster or oral presentations (i.e.: those that are being presented during the late-breaking session at the podium)
May an industry employee present on behalf of the authors?
- Yes, for non-accredited poster presentations (i.e.: those that are being presented in the poster hall)
- No, for accredited poster or oral presentations (i.e.: those that are being presented during the late-breaking session at the podium)
Is industry sponsored research allowed?
Yes; however, due to CME guidelines, only non-industry employees will be allowed to present if accepted for an Oral Presentation.
Is society sponsorship required for admission?
No
Are QR codes allowed on the posters?
No
Do you have any policy regarding the usage of brand names or trademarks in abstracts or posters?
Brand names, trademarks and logos are NOT allowed - only generic names may be used.
Will you accept an abstract presenting only the study design?
It would be preferable if the abstract included the results/read outs; however, if they are not available at the time of submission but will be presented at the conference, that would be acceptable.
What are the Embargo Rules, if any?
- None for encore presentations
- For primary disclosures, scientific dissemination must be reserved until after presentation at the conference. Press releases and media coverage are allowed in advance of the conference provided that data is not included.
Where will the abstracts be published?
All accepted abstracts will be published in the British Journal of Dermatology (BJD) as well as on the FDE Website.
What is the pre-conference abstract availability date/access venue?
Saturday, June 8, 2024 - 7:00 PM (ET)
What is the post-conference abstract availability date/access venue?
In perpetuity
Is there a language requirement for the abstracts?
English
Abstract Guidelines and Format
As you prepare your submission to the conference, please make note of the following details:
- All types of vitiligo and alopecia areata related research are eligible for submission.
- Abstract should address scientific questions, detail clinical observations, or contain primary scientific data.
- Encore presentations of data from previously presented research may be submitted.
- Abstracts must be submitted in Word format only.
- Abstracts must be submitted in English only.
Important:
- Please ensure that you include the title, author information including first and last name (middle initial if available), and author institution (name, city, state/province, and country)
- Titles should be in bold, sentence case
- Affiliations should be designated with superscript numbers
- Please include all sections indicated in the Abstract Template
- Please double-space
- Word Limit: 600 Words (word count does not include title, authors, author affiliations, references or disclosures)
- You may insert one (1) chart or graph. (Note: charts and graphs will be included on the FDE Website; however, they will not be included in the British Journal of Dermatology publicaton.)
Guidelines for Posters
The following should be completed by Friday, May 31, 2024, at 11:59 PM (ET) and uploaded via the link that will be provided in your acceptance email:
- A digital presentation of your poster in high-resolution PDF format must be provided.
- Posters may be formatted as:
- A conventional poster on a single slide to fit on a 16 x 9 PPT slide
- Posters may be formatted as:
- You may also submit an optional 3-minute video presentation of your poster that will be included on the FDE website. Video presentations should be provided in MP4 format.
- The presenter should not be an employee of an industry sponsor.
- You must agree to present the abstract if it is selected for poster presentation at the ReV Conference. This includes being present during the scheduled time of a poster session. Accepted posters will be accessible to delegates in person in the poster hall and on the FDE website.
- Posters/presentations generated by ChatGPT or other artificial intelligence software will not be accepted.
Guidelines for Oral Presentation Authors Should You be Accepted
You will receive notification the week of May 13, 2024, if your abstract has been accepted to be presented as an oral presentation. The following will be required to present during the in-person conference. Upon acceptance, you will be assigned a presentation time. Please see below for further details.
Please note: Presentations generated by ChatGPT or other artificial intelligence software will not be accepted.
The presenting author must:
- Agree to the Confidentiality Policy on behalf of all parties involved with the abstract and communicate this policy to all involved parties. The Confidentiality Policy applies to both standard and late-breaking data submission from the time of abstract submission.
- You will need to provide your oral presentation slides and disclosure information for CME approval by Wednesday, May 29, 2024 (11:59 PM ET).
- Oral presentations will be 5-7 minutes.
- Verify that, if necessary for the work reported, the clinical research represented in the abstract was approved by an appropriate ethics committee or institutional review board and that, if appropriate to the research, informed consent was obtained for all subjects.
- Verify that all coauthors are aware of the contents of the abstract and support its data.
- Agree, on behalf of all coauthors, to publication of the abstract in the final scientific program.
- For an abstract to be included in the final scientific program, it is mandatory for the presenting author to register for the conference and to settle payment within 72 hours of receiving the abstract acceptance. If accepted, you will receive a discount code via your oral presentation acceptance notification email.
- Agree to present IN PERSON at the ReV/RAA Conference in Chicago, IL, if the abstract is selected for Oral Presentation. This includes being present during the scheduled time of the oral session.
- Agree to list all potential conflicts of interest in the presentation if the abstract is accepted for oral presentation at the ReV Conference.
- Ensure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors.
- Enter the name of the clinical trial registry and the trial.